Dostarlimab, also known as Jemperli, has been approved in europe for use in combination with chemotherapy to treat advanced or recurrent endometrial cancer. The approval appears to be for first-line treatment and for all adult patients with this condition. However, the scope and specifics of the approval, including whether it has been finalized by the european commission or is still under review, are not entirely clear.